Loreclezole

®

MedChemExpress

| Cat. No.: | HY-105272 | | |
|--------------------|--------------------|----------|-------------------------------------|
| CAS No.: | 117857-45-2 | 1 | |
| Molecular Formula: | $C_{10}H_6Cl_3N_3$ | | |
| Molecular Weight: | 274.53 | | |
| Target: | GABA Recep | otor | |
| Pathway: | Membrane | Transpor | ter/Ion Channel; Neuronal Signaling |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |

SOLVENT & SOLUBILITY

| In Vitro | 0, (| DMSO : 110 mg/mL (400.68 mM; Need ultrasonic) H ₂ O : < 0.1 mg/mL (insoluble) | | | | | |
|----------|------------------------------|---|--------------------|-----------------|------------|--|--|
| | | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | | |
| | Preparing Stock Solutions | 1 mM | 3.6426 mL | 18.2129 mL | 36.4259 mL | | |
| | 5 mM | 0.7285 mL | 3.6426 mL | 7.2852 mL | | | |
| | 10 mM | 0.3643 mL | 1.8213 mL | 3.6426 mL | | | |
| | Please refer to the so | lubility information to select the app | propriate solvent. | | | | |
| In Vivo | | one by one: 10% DMSO >> 40% PE(ng/mL (7.58 mM); Clear solution | G300 >> 5% Tween-8 | 0 >> 45% saline | | | |
| | | one by one: 10% DMSO >> 90% cor ng/mL (7.58 mM); Clear solution | n oil | | | | |

| BIOLOGICAL ACTIV | |
|---------------------------|--|
| Description | Loreclezole, an antiepileptic compound, is a selective GABA _A receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit containing receptors ^{[1][2]} . |
| IC ₅₀ & Target | GABA _A receptor ^[1] . |
| In Vivo | Loreclezole (10, 25, 50 or 75 mg/kg, i.p. 60 min before measurement of seizure threshold) results in a dosedependent rise in seizure threshold as measured by the dose of pentylenetetrazolrequired to produce a convulsion 60 min later. Loreclezole also has the least effect on loss of muscle tone as measured by the "pull-up" test ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

Product Data Sheet

ĊI

ĊI

Ν.

N⁻

∠CI

| Animal Model: | Adult male Lister Hooded rats ^[3] . |
|-----------------|--|
| Dosage: | 10, 25, 50 or 75 mg/kg. |
| Administration: | IP, 60 min before measurement of seizure threshold. |
| Result: | Resulted in a dosedependent rise in seizure threshold as measured by the dose of |
| | pentylenetetrazolrequired to produce a convulsion 60 min later. |

REFERENCES

[1]. Wingrove PB, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4569-73.

[2]. Sanna E, et al. Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.

[3]. Green AR, et al. A behavioural and neurochemical study in rats of the pharmacology of loreclezole, a novel allosteric modulator of the GABAA receptor. Neuropharmacology. 1996;35(9-10):1243-50.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA